What Климонорм treats: main uses and benefits

Klimonorm is an example of a Sequential Combined Hormone Replacement Therapy (HRT), which is commonly used across conditions presenting with acute episodes and is considered relevant for easing symptoms related to systemic imbalance that may intensify temporarily. The main use of this type of medication may assist with managing the various manifestations of menopause in patients who still have their uterus.

The treatment is relevant for easing symptoms that interfere with daily comfort. This applies to clinical settings that involve acute or unstable symptom patterns, such as managing symptoms related to heightened physiological activity like hot flashes and night sweats, and addressing symptoms that interfere with daily functioning like mood swings, sleep disturbances, and vaginal dryness. The combination of an estrogen (like estradiol) and a progestogen (like levonorgestrel) is applied when appropriate when supportive symptom management is needed in women with an intact uterus.

Combined HRT contributes to improved comfort and supports general well-being during symptomatic phases. This therapy is commonly used to help with hot flushes, night sweats, and low mood. Furthermore, this supportive therapy may assist with the prevention of osteoporosis after menopause, which may be part of symptomatic management.

Quick Fact: Supports Management of Vasomotor Symptoms

This section explains the official eligibility and exclusion criteria for Klimonorm, based strictly on authoritative governmental regulatory documents.

Eligibility and Restrictions

The medicine is specifically indicated for use only by postmenopausal women who have an intact uterus. The formulation contains both an estrogen and a progestogen (estradiol valerate and levonorgestrel) to protect the uterine lining, which mandates the presence of the uterus for this specific product's use.

Contraindicated Populations

Klimonorm is formally contraindicated (must not be used) in several specific patient populations. These contraindications are tied to high-risk health conditions and include, but are not limited to:

• A history or current presence of breast cancer or any known or suspected estrogen-dependent malignant tumors (e.g., endometrial cancer).
• Current or past venous thromboembolism (e.g., DVT, pulmonary embolism) or known thrombophilic disorders (conditions increasing blood clot risk).
• Arterial thromboembolic disease, such as a recent heart attack or stroke.
• Active liver disease or a history of liver disease where liver function tests have not returned to normal.
• Undiagnosed abnormal genital bleeding or untreated endometrial hyperplasia.
• Known or suspected pregnancy or lactation (breastfeeding).

Use is restricted to postmenopausal women free of all these specific contraindications.

Interactions with other medicines and products

Official regulatory documents define specific drug and substance interactions for Klimonorm, which contains estradiol valerate and levonorgestrel.

---

Contraindicated Combinations

Klimonorm must not be used concomitantly with specific combination regimens for Hepatitis C Virus (HCV) infection that contain ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented risk of significant liver enzyme (ALT) elevations.

---

Exposure and Metabolism Interactions

Substances that induce hepatic enzymes, such as CYP3A4 inducers, can accelerate the metabolism of the hormonal components. This is officially documented to decrease the plasma concentrations of both estrogen and progestogen, potentially leading to a loss of therapeutic effect and the occurrence of breakthrough bleeding.

• Medicines noted: Certain antiepileptics and anti-infectives like Rifampicin. Patients using these drugs must be advised to utilize a back-up or alternative non-hormonal method.
• Herbal Products: The herbal supplement St. John's Wort (Hypericum perforatum) is documented as a known enzyme inducer that can similarly reduce the effectiveness of the hormones.

---

Other Pharmacodynamic Interactions

Estrogen components can affect the levels of plasma proteins, including Thyroxine-Binding Globulin (TBG). This effect may increase the requirement for thyroid hormone replacement therapy in patients taking levothyroxine.

---

The interaction profile primarily dictates restrictions related to enzyme induction and one specific contraindication involving HCV antiviral treatment, guiding the safe use of this hormonal product.

Mechanism of Action: Estrogen Component

Klimonorm provides exogenous estradiol valerate, which is metabolized to 17beta-estradiol. This active metabolite acts as an agonist, binding to and activating nuclear estrogen receptors ( ERalpha and ERbeta) in target cells. The resulting ligand-receptor complex translocates to the nucleus where it regulates gene transcription, thereby modulating the synthesis of proteins within estrogen-responsive tissues, including the hypothalamus, skin, and bone. In bone tissue, estrogens modulate the activity and differentiation of osteoclasts and osteoblasts, influencing the overall process of bone remodeling.

Mechanism of Action: Progestogen Component

The preparation also includes the progestogen levonorgestrel. Levonorgestrel binds to intracellular progesterone receptors (PR) located within the endometrium. This binding and subsequent receptor activation modifies gene expression patterns. This molecular mechanism ensures the specific antagonism of estrogen-induced proliferation within endometrial cells.

The administration of Климонорм is based on a fixed-dose, cyclic oral regimen. This approach is standardized for combined sequential hormone therapy.

Official Dosing and Administration

Instruction Domain	Detail
Route and Frequency	The medicine is taken orally once daily, adhering to a pre-set sequence of tablets.
Dosing Schedule	The regimen follows a 28-day course consisting of 21 consecutive days of active hormone tablets and a subsequent 7-day hormone-free interval. This structure ensures the sequential delivery of 2 mg estradiol valerate, with 0.150 mg levonorgestrel added in the second half of the active period.
Administration Timing	Each tablet must be taken at the same time every day to maintain consistent hormone exposure. The instructions do not mandate specific intake conditions related to meals.

Procedural Rules for Use

The core procedural instruction requires strict adherence to the sequential order of the tablets within the pack, starting with the estrogen-only phase and moving to the combined estrogen-progestin phase. Following the 7-day tablet-free interval, a new pack must be started immediately on the designated day. For a missed tablet, if the tablet is missed by more than 24 hours, the tablet should generally be discarded, and the scheduled intake resumed, as the integrity of the hormone sequence may be compromised. Dose adjustments for specific populations, such as older adults, are not predefined as different starting doses.

Research Evidence / Overview of Studies for Климонорм

---

Evidence for Use in Managing Menopausal Symptoms

Research has examined this type of sequential combined hormone therapy (HRT) for conditions characterized by fluctuating or episodic manifestations linked to menopause. Specifically, studies were conducted in trials assessing short-term or episodic symptom patterns, often using validated rating scales like the Menopause Rating Scale (MRS II) to track symptom intensity or variability over time. Other research explored patient-reported outcomes describing perceived discomfort related to mood and sleep disturbances.

Findings describe patterns observed in the studies regarding the frequency and intensity of symptoms reported by women during the observation period. Systematic reviews and meta-analyses, which have explored these outcomes related to systemic or functional imbalance across the HRT class, also contribute to the evidence. However, evidence is limited when considering product-specific randomized, placebo-controlled trials for this exact combination of estradiol and levonorgestrel.

---

Evidence for Bone Health and Osteoporosis Prevention

This therapy was studied for its role in examining bone mineral density and bone loss in postmenopausal women. The research included long-term observational studies and controlled trials that monitored physical outcomes related to bone structure. Specifically, studies examined changes in Bone Mineral Density (BMD) at sites like the spine and hip, requiring sustained follow-up over several years. This type of research was evaluated in women at risk of bone loss following natural or surgical menopause.

Findings describe the context of patient reporting related to bone health status. Large-scale trials reported general patterns regarding bone mass. The long-term effects are not fully established with data specific to this exact formulation, and the results apply only to the populations studied and are often considered in the context of general estrogen therapy principles.

---

Research on Endometrial Protection and Safety Endpoints

A key area of research for combined sequential HRT was evaluated in women who still had an intact uterus, focusing on established guidelines for uterine safety. These studies examined the role of the progestin component, levonorgestrel, specifically to oppose the proliferative action of estrogen on the uterine lining. Findings describe patterns observed in the studies where the progestin component describes cyclical changes in the uterine lining. Research also described the typical patterns of scheduled withdrawal bleeding in women using this sequential regimen.

Key Studies & References

1. Menopause: diagnosis and management (National Institute for Health and Care Excellence - NICE Guideline NG23)

Common questions about Климонорм (FAQ)

Q: What is the intended use of Klimonorm?

A: According to official regulatory sources, Klimonorm is intended for Hormone Replacement Therapy (HRT). Its main use is for treating symptoms associated with estrogen deficiency during and after menopause. It is also indicated for the prevention of postmenopausal osteoporosis (bone thinning) in patients who are at high risk of fractures and cannot use other specific treatments.

Q: Is Klimonorm a combined preparation?

A: Yes, Klimonorm is a combined hormone preparation. Official product information indicates that it contains an estrogen component (Estradiol valerate) and a progestogen component (Levonorgestrel). These components are formulated to be taken sequentially to mimic a woman's natural cycle.

Q: Can Klimonorm cause weight changes?

A: Regulatory documents mention that changes in body weight are listed as a known possible side effect of Klimonorm. This includes the possibility of both increases and decreases in weight. Patients are advised to review the official safety information for a complete list of possible effects.

Q: Does Klimonorm affect blood pressure?

A: Official product information indicates that an increase in blood pressure is a possible, though uncommon, side effect of taking Klimonorm. Because of this, patients are generally advised to have their blood pressure monitored regularly during HRT. Any concerns should be discussed with a qualified healthcare provider.

Q: What should I do if I forget to take a tablet?

A: Instructions for a missed dose are specifically detailed in the official product information, which defines a time window (e.g., 12 hours) within which a forgotten tablet may be taken. If the specified time window has been exceeded (e.g., 24 hours), the general advice is to disregard the missed tablet and resume the cycle at the usual time. Missing a tablet for too long may increase the risk of breakthrough bleeding.

How to Store and Dispose of Klimonorm

The storage and disposal of Klimonorm must strictly adhere to the conditions mandated by the official regulatory labeling to maintain product stability.

---

Storage Requirements

Klimonorm must be stored at a temperature below 25 °C. The tablets must be kept in the original package to ensure protection from light and moisture. This ensures the product maintains its 3-year labeled shelf-life. As a mandatory safety requirement, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused tablets must not be thrown away with household waste or disposed of in wastewater. The disposal of the medicinal product and any associated waste materials must be carried out in accordance with local requirements, such as through a designated pharmaceutical collection scheme.